- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00084708
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
A Phase I Study of Intravenous (IV) Calcitriol in Combination With ZD1839 (IRESSA®) in Refractory Solid Tumors
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Calcitriol may help tumor cells develop into normal cells. Dexamethasone may increase the effectiveness and decrease the side effects of gefitinib and calcitriol.
PURPOSE: This phase I trial is studying the side effects and best dose of calcitriol when given together with gefitinib or when given together with gefitinib and dexamethasone in treating patients with advanced solid tumors.
연구 개요
상세 설명
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD), toxic effects, and tolerability of calcitriol alone and in combination with gefitinib with or without dexamethasone in patients with advanced solid tumors.
Secondary
- Determine the pharmacokinetics and pharmacodynamics of these regimens in these patients.
- Determine any tumor responses in patients treated with these regimens.
OUTLINE: This is a dose-escalation study of calcitriol.
- Stage 1: Patients receive calcitriol IV over 1 hour on days 1, 15, and 22 and oral gefitinib once daily on days 8-28 during course 1. For all subsequent courses, patients receive calcitriol IV over 1 hour on days 1, 8, 15, and 22 and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of calcitriol with a fixed dose of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Stage 2: Patients receive calcitriol (beginning at 1 dose level below the MTD determined in stage 1) and gefitinib as in stage 1. Patients also receive oral dexamethasone once on the day before and twice on the day of each dose of calcitriol.
Cohorts 3-6 patients receive escalating doses of calcitriol with fixed doses of gefitinib and dexamethasone until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: A total of 21-36 patients will be accrued for this study within 1 year.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
New York
-
Buffalo, New York, 미국, 14263-0001
- Roswell Park Cancer Institute
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically confirmed advanced solid tumor
- Metastatic or unresectable disease
- Standard curative or palliative measures do not exist or are no longer effective
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2 OR
- Karnofsky 60-100%
Life expectancy
- More than 3 months
Hematopoietic
- WBC ≥ 3,000/mm^3
- Hemoglobin ≥ 8 g/dL
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin normal
- AST and ALT ≤ 2.5 times upper limit of normal
- No unstable or uncompensated hepatic disease
Renal
- Creatinine normal OR
- Creatinine clearance ≥ 60 mL/min
- No prior hypercalcemia
- No kidney, ureteral, or bladder stones within the past 10 years
- No unstable or uncompensated renal disease
Cardiovascular
- Ejection fraction ≥ 30%
- No heart failure or significant heart disease
- No significant arrhythmias
- No myocardial infarction within the past 3 months
- No unstable angina pectoris
- No symptomatic congestive heart failure
- No other unstable or uncompensated cardiac disease
Pulmonary
No evidence of clinically active interstitial lung disease
- Chronic, stable, asymptomatic, radiographic changes allowed
- No other unstable or uncompensated respiratory disease
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after study treatment
- Able to receive oral medication
- Willing to have serial skin biopsies
- No prior allergic reaction to compounds of similar chemical or biological composition to study drugs or other agents used in this study
- No ongoing or active infection
- No known severe hypersensitivity to gefitinib or any of its excipients
- No psychiatric illness or social situation that would preclude study compliance
- No other severe or uncontrolled systemic disease or concurrent illness that would preclude study participation
- No other significant clinical disorder or laboratory finding that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)
Chemotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
Endocrine therapy
- No other concurrent systemic glucocorticoid therapy
Radiotherapy
- More than 4 weeks since prior radiotherapy and recovered
Surgery
- Recovered from prior major surgery
- No prior nephrectomy
Other
- Recovered from all prior anticancer therapy
- More than 30 days since prior non-approved or investigational drugs
- More than 7 days since prior thiazides
No concurrent administration of any of the following:
- Combination antiretroviral therapy for HIV-positive patients
- Phenytoin
- Carbamazepine
- Barbiturates
- Rifampin
- Phenobarbital
- Hypericum perforatum (St. John's wort)
- Calcium supplements
- Thiazides
- Digoxin
- No other concurrent investigational or commercial anticancer agents or therapies
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
---|
최대 허용 용량
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Marwan Fakih, MD, Roswell Park Cancer Institute
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CDR0000365546
- RPCI-RPC-0207
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
덱사메타손에 대한 임상 시험
-
Vanderbilt University Medical Center종료됨
-
Ludwig-Maximilians - University of MunichAllergan완전한
-
Assiut University모집하지 않고 적극적으로
-
European Myeloma NetworkJanssen Pharmaceutica모집하지 않고 적극적으로경쇄(AL) 아밀로이드증, 3B기네덜란드, 그리스, 프랑스, 이탈리아